Fortrea Holdings (FTRE) Total Current Liabilities (2022 - 2026)
Fortrea Holdings (FTRE) reported Total Current Liabilities of $929.1 million for Q1 2026, down 7.01% on a YoY basis from $999.1 million in Q1 2025, and up 1.73% quarter-over-quarter from $913.3 million in Q4 2025.
Fortrea Holdings (FTRE) Total Current Liabilities (2022 - 2026) Analysis & Trends
Fortrea Holdings has reported Total Current Liabilities for 5 years, with the latest figure at $929.1 million in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities fell 7.01% year-over-year to $929.1 million; the trailing twelve-month figure through Mar 2026 stood at $929.1 million (down 7.01% YoY), and the FY2025 full-year result was $913.3 million, down 3.81% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $929.1 million, up from $913.3 million in the prior quarter.
- The five-year high for Total Current Liabilities was $999.1 million in Q1 2025, with the low at $699.0 million in Q4 2022.
- Historically, Total Current Liabilities has averaged $847.3 million across 5 years, with a median of $818.3 million in 2024.
- Annual changes were most pronounced in 2025 — Total Current Liabilities climbed 25.81% — and 2026, when it slipped 7.01%.
- Fortrea Holdings' Total Current Liabilities stood at $699.0 million in 2022, then increased by 11.36% to $778.4 million in 2023, then grew by 21.98% to $949.5 million in 2024, then retreated by 3.81% to $913.3 million in 2025, then grew by 1.73% to $929.1 million in 2026.
- The last three Total Current Liabilities figures came in at $929.1 million (Q1 2026), $913.3 million (Q4 2025), and $914.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.70 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 636.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 13.42 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 3.88 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 72.86 Mn |
| 10 | Fortrea Holdings | 1.43 Bn | 1.28 Bn | 123.60 Mn | 929.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 929.10 Mn |
| Dec 31, 2025 | 913.30 Mn |
| Sep 30, 2025 | 914.40 Mn |
| Jun 30, 2025 | 942.30 Mn |
| Mar 31, 2025 | 999.10 Mn |
| Dec 31, 2024 | 949.50 Mn |
| Sep 30, 2024 | 795.80 Mn |
| Jun 30, 2024 | 749.00 Mn |
| Mar 31, 2024 | 818.30 Mn |
| Dec 31, 2023 | 778.40 Mn |
| Sep 30, 2023 | 774.60 Mn |
| Jun 30, 2023 | 752.10 Mn |
| Dec 31, 2022 | 699.00 Mn |